Furthermore, we used subclass mapping analysis to contrast the expression profiles of the high-/low-score subgroups with a previously published dataset of 47 melanoma patients who accepted the immune checkpoint inhibitor therapy (CTLA-4 and PD-1). This evidence concerns the gene CTLA4 and melanoma.